On March 24, 2022 Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") reported that CEO Renée Aguiar-Lucander has subscribed for 175,000 shares through Calliditas’ warrant program 2018/2022 (Press release, Calliditas Therapeutics, MAR 24, 2022, View Source [SID1234610866]). Following the new subscription for shares, Renée Aguiar-Lucander’s shareholding in the company will amount to 593,000 common shares.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

All members of the management team who are warrant holders in the program have today exercised their opportunity to subscribe for shares in the 2018/2022 warrant program, which comprises 856,586 warrants and can be exercised until 31 March 2022. To partially finance the share subscriptions, warrant holders in the program, including the CEO and some members of the management, have sold warrants. The sale of the block, which consisted of the equivalent of 488,000 shares, was made outside the market to a tier one long-term investor.

"I am very excited about the company’s development and success to date, especially as Calliditas now has an approved product on the market in the US, partnerships and upcoming potential market approvals in several other geographies and an exciting late stage pipeline, which holds the promise of continued significant value creation." says Renée Aguiar Lucander, CEO of Calliditas Therapeutics. "I also note that all warrant holders in the management team subscribed for shares according to their ability in the warrant program, which reflects everyone’s commitment to the future growth of Calliditas."

If all shares within the framework of the warrant program 2018/2022 are subscribed for, Calliditas will receive SEK 63.6 million in cash.